In a podcast interview, David Ricks, the CEO of Eli Lilly, offered a wealth of insights into the pharmaceutical industry. He highlighted that GLP-1-related businesses currently constitute roughly 80% of Lilly's market value. Beyond their roles in lowering blood sugar and aiding weight loss, these drugs are also being investigated for additional therapeutic applications, including anti-inflammatory effects, addiction intervention, and metabolic disease improvement. Oral GLP-1 medications and direct-to-patient sales models represent key strategies for Lilly to broaden its drug accessibility. The company has invested in a biomedical supercomputer outfitted with over a thousand NVIDIA GPUs and is partnering with NVIDIA to set up an AI innovation lab. Nevertheless, Ricks expressed that humans currently understand only about 10%-15% of biological knowledge, and AI is not yet capable of reliably predicting complex biological systems. To fully unlock AI's potential in drug development, data must be enriched through automated robotic experiments. He also noted that China's contribution to the global drug development pipeline has surged to around 30%, with Chinese pharmaceutical companies excelling in drug iteration and optimization. Ricks urged the United States to prioritize competitiveness in biomedical innovation and underscored the necessity of bolstering clinical data protection for innovative drugs to guarantee reasonable returns for original R&D firms. Furthermore, he pointed out that the exorbitant cost of new drug development primarily stems from the time-intensive patient recruitment process for late-stage clinical trials, and Lilly is striving to streamline this process through digital methods.